Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Florencia L. Mauro"'
Autor:
Sofia Bruni, Florencia L Mauro, Cecilia J Proietti, Rosalia I Cordo-Russo, Martin A Rivas, Gloria Inurrigarro, Agustina Dupont, Dario Rocha, Elmer A Fernández, Ernesto Gil Deza, Daniel Lopez Della Vecchia, Sabrina Barchuk, Silvina Figurelli, David Lasso, Adrián D Friedrich, María C Santilli, María V Regge, Gabriel Lebersztein, Claudio Levit, Fabiana Anfuso, Teresa Castiglione, Patricia V Elizalde, Maria F Mercogliano, Roxana Schillaci
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 3 (2023)
Background The success of HER2-positive (HER2+) breast cancer treatment with trastuzumab, an antibody that targets HER2, relies on immune response. We demonstrated that TNFα induces mucin 4 (MUC4) expression, which shields the trastuzumab epitope on
Externí odkaz:
https://doaj.org/article/260a8bffb8ab415c8e86847e61a3c8b1
Publikováno v:
Cancer Research. 83:2273-2273
Clinical trials showed that trastuzumab deruxtecan (T-DXd) provides durable responses for patients with HER2+ and HER2 low metastatic breast cancer (BC), determined by immunohistochemistry. Approximately 50% of patients with HER2+ metastatic BC were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::928b480f218a6f64fa8ebdcd5040488f
https://doi.org/10.1158/1538-7445.am2023-2273
https://doi.org/10.1158/1538-7445.am2023-2273
Autor:
Sofia Bruni, Florencia L. Mauro, Maria F. Mercogliano, Cecilia J. Proietti, Carla Adami, Agustina Dupont, Gloria Inurrigarro, Rosalia Cordo Russo, Patricia V. Elizalde, Roxana Schillaci
Publikováno v:
Cancer Research. 82:2047-2047
HER2+ is a breast cancer (BC) subtype characterized by the overexpression/amplification of HER2. Patients receive trastuzumab (Tz) but many (27-42%) do not achieve an objective response. We demonstrated that the overexpression of TNFɑ induces Tz res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::17f583939b3bf11009d4ea630e781794
https://doi.org/10.1158/1538-7445.am2022-2047
https://doi.org/10.1158/1538-7445.am2022-2047
Autor:
María Florencia Mercogliano, Roxana Schillaci, Sofía Bruni, Patricia V. Elizalde, Florencia L. Mauro
Publikováno v:
Cancers, Vol 13, Iss 564, p 564 (2021)
Cancers
CONICET Digital (CONICET)
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
Cancers
CONICET Digital (CONICET)
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
Tumor necrosis factor alpha (TNFα) is a pleiotropic cytokine known to have contradictory roles in oncoimmunology. Indeed, TNFα has a central role in the onset of the immune response, inducing both activation and the effector function of macrophages
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79c8bd35ab85c0688441f77ab78f39f9
https://www.mdpi.com/2072-6694/13/3/564
https://www.mdpi.com/2072-6694/13/3/564
Autor:
Roxana Schillaci, Sofía Bruni, María Florencia Mercogliano, Agustina Roldán Deamicis, Patricia V. Elizalde, Mara De Martino, Florencia L. Mauro
Publikováno v:
Cancer Research. 80:1913-1913
Lapatinib (LAP), a dual EGFR/HER2 tyrosine kinase inhibitor, is used as second-line therapy in women with HER2+ breast cancer (BC), but less than 25% of the patients achieve an objective response. An alternative therapeutic approach is needed to over
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4b1c2610e1b9f57117cf852a4b381771
https://doi.org/10.1158/1538-7445.am2020-1913
https://doi.org/10.1158/1538-7445.am2020-1913